Inhibition of protein synthesis is one of the validated and highly successful targets for inhibition of bacterial growth; this mechanism is atarget of a large number of clinical drugs. Ribosomal protein S4, a primary protein, is a potential target for the discovery of antibacterialagents. We describe, using an antisense-sensitized
rpsD Streptomyces aureus strain, the discovery and activity of lucensimycins A and B.